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Cholestenoic acids are formed as intermediates in metabolism of cholesterol to bile acids,
and the biosynthetic enzymes that generate cholestenoic acids are expressed in the
mammalian CNS. Here, we evaluated the cholestenoic acid profile of mammalian
cerebrospinal fluid (CSF) and determined that specific cholestenoic acids activate the liver
X receptors (LXRs), enhance islet-1 expression in zebrafish, and increase the number of
oculomotor neurons in the developing mouse in vitro and in vivo. While 3b,7a-
dihydroxycholest-5-en-26-oic acid (3b,7a-diHCA) promoted motor neuron survival in an
LXR-dependent manner, 3b-hydroxy-7-oxocholest-5-en-26-oic acid (3bH,7O-CA) promoted
maturation of precursors into islet-1+ cells. Unlike 3b,7a-diHCA and 3bH,7O-CA, 3b-
hydroxycholest-5-en-26-oic acid (3b-HCA) caused motor neuron cell loss in mice. Mutations
in CYP7B1 or CYP27A1, which encode enzymes involved in cholestenoic acid metabolism,
result in different neurological diseases, hereditary spastic paresis type 5 (SPG5) and
cerebrotendinous xanthomatosis (CTX), respectively. SPG5 is characterized by spastic
paresis, and similar symptoms may occur in CTX. Analysis of CSF and plasma from
patients with SPG5 revealed an excess of the toxic LXR ligand, 3b-HCA, while patients with
CTX and SPG5 exhibited low levels of the survival-promoting LXR ligand 3b,7a-diHCA.
Moreover, 3b,7a-diHCA prevented the loss of motor neurons induced by 3b-HCA in the
developing mouse midbrain in vivo.Our results indicate that specific cholestenoic acids
selectively work on motor neurons, via LXR, to regulate the balance between survival […]
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Introduction
The vertebrate CNS is composed of a wide variety of neurons 
that are generated following tightly regulated developmental 
programs. Characterization of the function and specificity of mol-
ecules working on distinct neuronal populations is thus essential 
in order to enhance our understanding of how such complexity is 
achieved in the developing brain and how it is maintained in the 
adult brain. One means of developmental and adult regulation is 
via nuclear receptors. Examples of nuclear receptors expressed in 
embryonic and adult brain having both a developmental role (1) 
and a function in the adult brain (2) are the liver X receptors 
(LXRα and LXRβ), which are activated by oxysterols (3, 4). Analy-
sis of double-knockout Lxra–/–Lxrb–/– mice revealed that LXRs are 
required for neurogenesis during ventral midbrain (VM) develop-
ment (1). Moreover, adult male Lxrb–/– show progressive accumu-
lation of lipids in the brain and loss of spinal cord motor neurons, 
suggestive of a neuroprotective role of LXRs and their ligands on 
adult motor neurons (5). Similarly, the number of islet-1+ oculomo-
tor neurons is lower in the developing midbrain of Lxra–/–Lxrb–/– 
mice, indicating a role of LXRs not only in the maintenance of 
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tion–mass spectrometry (LC-ESI-MS) analysis. We hereby report 
the exact identity of 16 oxysterols and downstream metabolites, 
including cholestenoic acids, found in human CSF (Supplemen-
tal Table 1; supplemental material available online with this article; 
doi:10.1172/JCI68506DS1). The most abundant of these metabo-
lites (19.48–0.40 ng/ml; Supplemental Figure 1) were 7α-hydroxy-
3-oxocholest-4-en-26-oic acid (7αH,3O-CA), 3β-hydroxycholest-5-
en-26-oic acid (3β-HCA), and 2 newly identified metabolites in CSF, 
3β,7α-diHCA and 3β,7β-dihydroxycholest-5-en-26-oic acid (3β,7β-
diHCA). Precursors of these acids, including 26-HC and newly 
identified 7α,26-dihydroxycholesterol (7α,26-diHC; cholest-5-ene-
3β,7α,26-triol) and 7α,26-dihydroxycholest-4-en-3-one (7α,26-
diHCO), were also found, but at lower levels (0.15–0.03 ng/ml). 
Our results thus identified 4 novel oxysterol metabolites in human 
CSF that were downstream of 26-HC (Figure 1A). 26-HC is metabo-
lized via 7α,26-diHC and 7α,26-diHCO, or via 3β-HCA and 3β,7α-
diHCA, to 7αH,3O-CA. While 26-HC can cross the blood-brain 
barrier (BBB) and enter the brain from the circulation (25), 7αH,3O-
CA traverses the BBB and is exported from the brain (26). Very low 
levels of 24S-hydroxycholesterol (24S-HC; cholest-5-ene-3β,24S-
diol), 25-hydroxycholesterol (25-HC; cholest-5-ene-3β,25-diol), 
and newly identified 7α,25-dihydroxycholesterol (7α,25-diHC; 
cholest-5-ene-3β,7α,25-triol) and 7α,25-dihydroxycholest-4-en-3-
one (7α,25-diHCO) were also found in CSF (0.08–0.03 ng/ml).
Reduced levels of 7α-hydroxylated cholestenoic acids in CSF 
and plasma/serum of human patients with SPG5. SPG5 presents 
with upper motor neuron signs and results from mutations in 
CYP7B1, encoding the oxysterol 7α-hydroxylase responsible for 
7α-hydroxylation of side-chain oxidized sterols that is required 
for extrahepatic synthesis of 7αH,3O-CA and its precursor, 3β,7α-
diHCA (Figure 1A and ref. 18). In order to examine the pathogenic 
role of such mutations, we sought to identify alterations in oxy-
sterol and cholestenoic acid profiles in CSF and plasma from these 
patients and then examine the biological activities of the altered 
metabolites. We first studied the CSF from 3 patients with SPG5 
(see Supplemental Table 3 for patient clinical data). Elevated lev-
els of the CYP7B1 substrates 25-HC (P < 0.10), 26-HC (P < 0.07), 
and 3β-HCA (P < 0.02), as well as reduced levels of its products, 
3β,7α-diHCA (P < 0.03) and 7αH,3O-CA (P < 0.001), were found 
compared with 18 individual control subjects; similar results were 
found when the SPG5 patients were compared with 2 healthy car-
rier heterozygotes with a single mutation in CYP7B1 (Figure 1, 
F–I, and Supplemental Table 1). When plasma was analyzed 
from 9 SPG5 patients (8, 10, 14), significantly elevated 25-HC 
(P < 0.03), 26-HC (P < 0.001), and 3β-HCA (P < 0.02) and reduced 
3β,7α-diHCA (P < 0.001) and 7αH,3O-CA (P < 0.02) were found 
compared with control subjects (Figure 1, B–E, and Supplemental 
Table 2). Similar differences were found between patient samples 
and 3 healthy carriers. This indicates that for these metabolites, 
plasma represents a good surrogate for CSF. However, while 
3β,7α-diHCA and 7αH,3O-CA in the CNS is normally derived from 
26-HC, that found in the circulation can be derived via either the 
26-HC or the 7α-hydroxycholesterol (7α-HC; cholest-5-ene-3β,7α-
diol) pathway (acidic and neutral, respectively) of bile acid biosyn-
thesis (18). Thus, in SPG5 patients (CYP7B1 mutation), the liver-
specific 7α-hydroxylase CYP7A1 (neutral pathway) accounts for 
the residual content of 3β,7α-diHCA and 7αH,3O-CA found in the 
adult motor neurons, but also in their development (1). In agree-
ment with these findings, enzymes involved in the synthesis of 
cholesterol and oxysterols, such as 2,3-oxidosqualene-lanosterol 
cyclase, are localized in islet-1+ oculomotor neurons in the mouse 
VM at E11.5 (1). In addition to the above, we recently found that 
oxysterols and other endogenous brain LXR ligands are suffi-
cient to regulate neurogenesis in the developing VM (1, 6). While 
endogenous brain LXR ligands have been identified and found to 
regulate the development of midbrain dopamine neurons and red 
nucleus neurons (6), to date, no endogenous ligand capable of reg-
ulating the survival of motor neurons in vivo has been identified. 
In a recent study, we found that cholesterol metabolites that had 
the capacity to activate LXRs can be identified in human cerebro-
spinal fluid (CSF) (7). In order to identify novel LXR ligands that 
regulate motor neuron function, we delved deeper into the human 
CSF sterolome and examined plasma of patients with 2 different 
human diseases associated with upper motor neuron degenera-
tion, hereditary spastic paresis type 5 (SPG5) and cerebrotendi-
nous xanthomatosis (CTX). These diseases result from mutations 
in the cytochrome P450 (CYP) genes CYP7B1 and CYP27A1, 
respectively (8–17). The enzymes coded by these genes are respon-
sible for 7α-hydroxylation of oxysterols and (25R),26-hydroxyl-
ation of sterols, respectively, reactions that generate further oxy-
sterols and ultimately cholestenoic acids (Figure 1A and ref. 18). 
Note that we have adopted the sterol nomenclature recommended 
by the lipid maps consortium: 26-hydroxycholesterol (26-HC) 
refers to cholest-(25R)-5-en-3β,26-diol; similarly, carboxylic acids 
that introduce 25R stereochemistry to the side-chain are at C-26 
(19). We found that specific cholestenoic acids with a 3β-hydroxy-
5-ene, but not a 3-oxo-4-ene, structure activated LXRα and LXRβ 
in neuronal cells, increased expression of islet-1, a transcription 
factor required for the development of motor neurons (20–22), 
and promoted the survival of islet-1+ oculomotor neurons. More-
over, these effects were abolished by knockdown or knockout of 
the LXR-encoding genes in zebrafish or in rodent models, respec-
tively. In addition, we showed that patients with CTX and SPG5 
are unable to synthesize normal amounts of the LXR ligand 3β,7α-
dihydroxycholest-5-en-26-oic acid (3β,7α-diHCA), a cholestenoic 
acid that we found to promote neuronal survival. This is of interest 
in relation to the fact that patients with SPG5 present with motor 
neuron degeneration and spastic paraplegia. Patients with CTX 
may sometimes also present with spasticity, possibly due to upper 
motor neuron degeneration. Our findings may have important 
implications for neurological diseases leading to motor neuron 
degeneration, since LXR ligands, as well as inhibitors of specific 
biosynthetic enzymes in the cholestenoic acid biosynthetic and 
metabolic pathways, may be useful pharmaceuticals for the treat-
ment of motor neuron disorders.
Results
Specific cholestenoic acids are abundant in human CSF. We have 
previously shown that cholestenoic acids are abundant in human 
plasma (23, 24) and that human CSF also contains specific chole-
stenoic acids (7). Surprisingly, in CSF, the levels of cholestenoic 
acids were higher than those of oxysterols. In this study, we delved 
deeper into the CSF sterolome, particularly into the cholestenoic 
acid portion, using liquid chromatography–electrospray ioniza-
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levels of toxic 3β-hydroxy-5-ene acids, may contribute to the pro-
gressive liver disease in these patients at an early age.
CTX is a second human disease that may present with signs 
of motor neuron loss. It is characterized by mutations in CYP27A1. 
We found that the plasma of patients with CTX was essentially 
devoid of 26-HC and the downstream cholestenoic acids (Fig-
ure 1, B–E, and Supplemental Table 2). As reported previously 
(33), elevated levels of 7α-HC plus 7α-hydroxycholest-4-en-3- 
one (7α-HCO) and/or 7α,12α-dihydroxycholesterol (7α,12α-diHC; 
cholest-5-ene-3β,7α,12α-triol) plus 7α,12α-dihydroxycholest-4-
en-3-one (7α,12α-diHCO) were observed (Supplemental Table 2). 
The absence of cholestenoic acids in plasma indicates an inabil-
ity to biosynthesize C27 acids in extrahepatic steroidogenic tissue, 
including the CNS.
circulation. We previously investigated the plasma oxysterol and 
cholestenoic acid profile of 3 infants with mutations in CYP7B1 
(Supplemental Table 2) resulting in oxysterol 7α-hydroxylase 
deficiency (O7AHD) and neonatal liver disease (27–30), as well 
as SPG5 in adults (31). The first identification of CYP7B1 muta-
tions were found in a child with severe cholestasis (32), defining 
a new inborn error of bile acid biosynthesis. As expected by the 
absence of functional CYP7B1 in these patients, we found very low 
plasma levels of 3β,7α-diHCA (P < 0.001; Figure 1D and Supple-
mental Table 2), as described above for SPG5. These patients also 
had considerably elevated plasma levels of 24S-HC, 25-HC, and 
26-HC and high levels of hepatotoxic 3β-hydroxychol-5-en-24-
oic acid (3βH-Δ5-BA) compared with SPG5 patients and controls. 
These findings suggest that additional factors, including increased 
Figure 1. Biosynthesis of cholestenoic acids in brain and levels of cholestenoic acids in the circulation and CSF. (A) Suggested metabolic pathway for 
the biosynthesis of 3β-HCA, 3β,7α-diHCA, 3β,7β-diHCA, and 7αH,3O-CA. Sterols are abbreviated according to cholesterol (C), cholest-4-en-3-one (CO), and 
cholesten-26-oic acid (CA) structures; numbers (with Greek letters) indicate the location of hydroxy (H) and oxo (O) groups. The enzymes in the pathway 
are indicated. With the exception of the epimerase, each enzyme is known to be expressed in brain. Enzyme defects in CTX and SPG5 are depicted by solid 
bars across arrows. Metabolites that are toxic toward neurons (red) or neuroprotective (green) are indicated. (B–E) Levels of (B) 26-HC, (C) 3β-HCA, (D) 
3β,7α-diHCA, and (E) 3β,7β-diHCA in plasma/serum from control subjects (Cn; n = 50), CTX patients (n = 4), SPG5 patients (Sp; n = 9), SPG5 carriers (Sc;  
n = 3) and infants with O7AHD (7a; n = 3). (F–I) Levels of (F) 26-HC, (G) 3β-HCA, (H) 3β,7α-diHCA, and (I) 3β,7β-diHCA in CSF from control subjects (n = 18), 
SPG5 patients (n = 3), and SPG5 carriers (n = 2). Measurements were made by LC-ESI-MS (see Supplemental Tables 1 and 2). *P < 0.05, **P < 0.01,  
***P < 0.001 vs. control, Dunnett T3 test.
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and LXRβ in neural cells. We previously found that 3β-HCA acti-
vates LXR (7) and here observed that 3β,7α-diHCA, its isomer 
3β,7β-diHCA, and the necessary intermediate for the intercon-
version of the isomers, 3β-hydroxy-7-oxocholest-5-en-26-oic acid 
(3βH,7O-CA), had the ability to activate both LXRs and therefore 
act as LXR ligands in neural cells (Figure 2A and Supplemental 
Figure 2, A and B). 3β,7α-diHCA was the most potent choleste-
noic acid, exhibiting 61% activity/efficacy toward LXRβ activation 
compared with the known LXR ligand 22R-hydroxycholesterol 
(22R-HC; cholest-5-ene-3β,22R-diol), followed by 3β-HCA and 
3β,7β-diHCA (Supplemental Figure 2B). However 3β,7β-diHCA 
In summary, our data showed specific changes in 7α-hydrox-
ylated cholestenoic acids in plasma of CTX and SPG5 patients; we 
thus decided to examine their effect on neural function.
Specific cholestenoic acids are ligands to LXRα and LXRβ in neu-
ral cells. In order to gain insights into the mechanism by which 
alterations in cholesterol metabolism causes neurological disease, 
we studied whether any of the cholestenoic acids present at high 
levels in control human CSF and deregulated in CSF or plasma 
of SPG5 or CTX patients work as LXR ligands. We thus focused 
on 26-HC, 3β-HCA, 3β,7α-diHCA, its isomer 3β,7β-diHCA, and 
7αH,3O-CA (Figure 1A) and tested their capacity to activate LXRα 
Figure 2. Analysis of the nuclear receptor acti-
vational capacity of oxysterols and cholestenoic 
acids. (A) Luciferase activity in SN4741 neural cells 
transfected with an LXR-responsive luciferase 
reporter construct (LXRE) with or without LXRα 
and stimulated for 24 hours with 22R-HC (10 μM), 
a known LXRα ligand (3, 4), or the compounds 
indicated. (B) Similar assay in cells transfected with 
an FXR-responsive luciferase reporter construct 
(FXRE) with or without FXR and stimulated for 
24 hours with CDCA, a known FXR ligand, or the 
compounds indicated. (C) Additional luciferase 
assays performed as in A with or without addition 
of the LXR antagonist GGPP (10 μM) along with the 
indicated cholesterol metabolites (10 μM each). 
Values in A–C are fold activation over the basal 
LXRE or FXRE luciferase activity (set to 1) (n = 3). 
*P < 0.05, **P < 0.01 vs. vehicle or as indicated by 
brackets, Mann-Whitney test. (D) TR-FRET LXRβ 
coactivator assay, used to determine the binding 
affinity of cholestenoic acids as well as the known 
LXR ligands GW3965 and 24,25-EC toward the 
LXRβ-LBD (n = 3). The 520:495 TR-FRET ratio was 
determined as described in Methods. *P < 0.05 vs. 
vehicle for ≥10 μM 3β,7α-diHCA, ≥10 μM 3β,7β-
diHCA, ≥10 μM 3β-HCA, ≥5 μM 24,25-EC, and  
≥5 μM GW3965, Mann-Whitney test. (E) 3β,7α-
diHCA, 3β,7β-diHCA and 3β-HCA induced 
significant increases in Abca1, Abcg1, and Srebf1 
in SN4741 cells (n = 3). *P < 0.05, **P < 0.01 vs. 
vehicle, Mann-Whitney test.
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to a similar degree as 22R-HC, while 3β,7β-diHCA and 3β-HCA 
induced transcription, but to a lesser extent (Figure 2E). These 
results provide further proof that 3β-HCA, 3β,7α-diHCA, and 
3β,7β-diHCA are specific LXR ligands in neural cells.
3β,7α-diHCA and 3βH,7O-CA increase islet-1 expression in 
islet-1–GFP zebrafish embryos. Having established that choleste-
noic acids that are altered in CTX or SPG5 can activate LXRs in 
vitro, we next sought to identify their effect in vivo. In particu-
lar, we focused on the expression of islet-1, a transcription factor 
expressed in all postmitotic motor neurons (20, 37) and required 
for multiple aspects of motor neuron development, including 
motor neuron specification, motor column formation, axonal 
growth, and maintenance of spinal motor neuron identity (38). 
We used transgenic zebrafish embryos expressing GFP driven by 
the isl1 gene promoter/enhancer sequences (Tg[isl1:GFP]) (39, 
40) to screen for biologically active compounds in vivo. Previ-
ous studies have indicated that islet-1 protein is required for the 
formation of zebrafish primary motor neurons and is conserved 
throughout vertebrate evolution (21). Treatment of Tg[isl1:GFP] 
embryos with the weak LXR ligands 3β-HCA and 3β,7β-diHCA, 
as well as CDCA, the most potent FXR ligand, had a deleteri-
ous toxic effect that impaired survival and precluded further in 
vivo analysis. Interestingly, we found that 2 LXR agonists, 3β,7α-
diHCA and 3βH,7O-CA, increased islet-1–GFP expression, but 
had no significant effect on the number of islet-1+ cells, in the dif-
ferent cranial nerves examined (loci III, IV, V, VII, and X; Figure 3, 
A and B). These effects were specific, as 7αH,3O-CA, which is 
not an LXR ligand, failed to regulate islet-1–GFP expression (Fig-
ure 3B). Notably, the increase in islet-1–GFP expression observed 
in response to the specific acidic compounds was evident in all 
cranial nerves studied (Figure 3B). Importantly, the increased 
islet-1–GFP expression in response to 3β,7α-diHCA and 3βH,7O-
CA was also accompanied by an increased level of isl1 mRNA, as 
assessed by quantitative PCR (Figure 3C). To further verify our 
results, we examined whether these cholestenoic acids regulated 
the in vivo expression of endogenous LXR target genes, such as 
abca1. Our results showed enhanced expression of abca1 by both 
3β,7α-diHCA and 3βH,7O-CA, but not by 7αH,3O-CA (Figure 
3D). Finally, in order to determine whether these effects are actu-
ally mediated by LXRs, we performed lxr morpholino (MO) injec-
tions in Tg[isl1:GFP] zebrafish. Interestingly, we found that lxr MO 
injections abolished the in vivo increase in islet-1–GFP levels by 
3β,7α-diHCA and 3βH,7O-CA, compared with control scrambled 
MO (Supplemental Figure 4). Thus, our data showed that chole-
stenoic acids are capable of activating endogenous LXR target 
genes in vivo and regulate the in vivo expression of islet-1 in brain 
motor neurons via LXR.
3β,7α-diHCA and 3βH,7O-CA increase, whereas 3β,7β-diHCA 
and 3β-HCA decrease, the number of rodent oculomotor neurons in 
vitro. In order to determine the functional relevance of our find-
ings in mammalian cells, we examined whether any of the chole-
stenoic acids present in human CSF and implicated in motor neu-
ron loss are also capable of regulating islet-1 expression in mouse 
primary brain progenitor cultures. We first performed dose-
response analysis of the cholestenoic acids of interest, using a 
wide range of concentrations; whereas 3β,7β-diHCA and 3β-HCA 
caused loss of islet-1+ cells in the cultures, equimolar concentra-
had the lowest 50% effective concentration (EC50), followed 
by 3β,7α-diHCA and 3β-HCA. In addition, we confirmed in our 
system the capacity of 24S-HC and 25-HC to activate LXR and 
observed that 26-HC had no significant effect. We also tested the 
activational capacity of 7αH,3O-CA, its 7β-isomer, 7β-hydroxy-
3-oxocholest-4-en-26-oic acid (7βH,3O-CA), and the precursors 
7α,26-diHC and 7α,26-diHCO, none of which showed significant 
activity (Figure 2A and Supplemental Figure 2A). Moreover, in 
order to examine whether the identified acidic ligands exert their 
effect by binding to LXR, we used the LXR antagonist geranylgera-
nyl pyrophosphate (GGPP; ref. 34), which blocked their activity 
(Figure 2C), indicating that the acids are indeed LXR ligands. The 
activity of the known LXR ligands 22R-HC and 25-HC was simi-
larly blocked. In order to confirm that the cholestenoic acids are 
indeed agonists to LXR, we tested the LXRβ activational capac-
ity of 3β,7α-diHCA, 3β,7β-diHCA, or 3β-HCA in combination with 
22R-HC. No additive effect was observed (Supplemental Figure 
3A), which indicates that these cholestenoic acids work, as does 
22R-HC, via LXR. To further examine the specificity of the cho-
lestenoic acids described above, farnesoid X receptor (FXR) lucif-
erase reporter assays were performed (Figure 2B). As previously 
described (35), chenodeoxycholic acid (CDCA; 3α,7α-dihydroxy-
5β-cholan-24-oic acid) activated FXR. Interestingly, 3βH-Δ5-BA 
(36), a cholesterol metabolite identified in plasma (Supplemen-
tal Table 2), also activated FXR, but was less potent than CDCA. 
However, none of the other compounds tested activated the FXR 
luciferase reporter or modulated the activity of CDCA in neural 
cells (Figure 2B and Supplemental Figure 3B). Thus, the chole-
stenoic acids do not exert their effect via modulating the activity 
of the FXR nuclear receptor or its ligands. Similarly, cholestenoic 
acids did not activate luciferase reporter assays under the con-
trol of a DR5 element (activated by Nur-related factor 1/retinoid 
X receptor [NURR1/RXR] heterodimers), whereas 9-cis-retinoic 
acid (9-cis-RA) activated this reporter (Supplemental Figure 2D). 
Furthermore, while lithocholic acid (LCA; 3α-hydroxy-5β-cholan-
24-oic acid) activated a vitamin D receptor (VDR) luciferase 
reporter, none of the cholestenoic acids tested showed any signifi-
cant effect on VDR activation in neural cells (Supplemental Figure 
2C). Thus, our results indicate that 3β-HCA (7), 3β,7α-diHCA, and 
3β,7β-diHCA are specific LXR ligands in neural cells.
Specific cholestenoic acids bind and activate LXR. In order to 
show that specific cholestenoic acids directly interact with LXR, 
we performed a binding and activation fluorescence resonance 
energy transfer (FRET) assay, in which ligand binding to the ligand 
binding domain (LBD) of LXRβ (referred to herein as LXRβ-LBD) 
recruits a fluorescent coactivator. 3β,7α-diHCA induced FRET, 
in a dose-dependent manner, to a greater extent than the other 
acids, but to a lesser extent than the known LXR ligands GW3965 
and 24S,25-epoxycholesterol (24,25-EC; 3β-hydroxycholest-5-en-
24S,25-epoxide) (Figure 2D). The respective efficacy (GW3965-
normalized) and EC50 values were 1 and 4.04 μM for GW3965, 
0.79 and 4.94 μM for 24,25-EC, 0.41 and 4.16 μM for 3β,7α-
diHCA, 0.25 and 4.51 μM for 3β,7β-diHCA, and 0.27 and 3.83 
μM for 3β-HCA. To provide further evidence that cholestenoic 
acids are LXR ligands in neural cells, we treated neural cells with 
the individual acids for 3 hours and measured Abca1, Abcg1, and 
Srebf1 transcript levels. 3β,7α-diHCA increased transcripts levels 
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tions of 3β,7α-diHCA and 3βH,7O-CA increased islet-1+ oculomo-
tor cell numbers (Figure 4A). EC50 values were 5.21 μM for 3β,7α-
diHCA and 3.58 μM for 3βH,7O-CA, and IC50 values were 4.44 μM 
for 3β,7β-diHCA and 2.63 μM for 3β-HCA. Moreover, islet-1+ cells 
coexpressed the transcription factor NKX6.1 as well as choline 
acetyltransferase (ChAT) (Figure 4B and data not shown), which 
indicates that they are bona fide oculomotor neurons. Time-
course analysis confirmed the stimulatory effect of 3β,7α-diHCA 
and 3βH,7O-CA, as well as the toxic effect of 3β,7β-diHCA and 
3β-HCA, over a range of incubation times (Supplemental Figure 
5A). The number of oculomotor neurons peaked after 2 days in 
culture and leveled thereafter. These results confirmed in rodent 
cells the dual effects of cholestenoic acids first observed in zebra-
fish, where 3β,7β-diHCA and 3β-HCA caused death, whereas 
3β,7α-diHCA and 3βH,7O-CA regulated islet-1 expression. Thus, 
our data provide further evidence of the differential effect of cho-
lestenoic acids on islet-1+ oculomotor neurons. Interestingly, the 
effects of 3β,7α-diHCA and 3βH,7O-CA were specific, as they did 
not affect the number of other midbrain neurons, such 
as tyrosine hydroxylase–positive (TH+) dopamine 
neurons, GABAergic neurons, or red nucleus neurons 
in the cultures (data not shown). In order to examine 
whether the effects of 3β,7α-diHCA and 3βH,7O-CA 
were specifically mediated by LXR receptors in the 
rodent brain, we performed progenitor brain cultures 
from Lxra–/–Lxrb–/– mice. Remarkably, the effects of 
3β,7α-diHCA and 3βH,7O-CA (at their most efficient 
concentration) on islet-1+ neurons were eliminated 
(Figure 4C), confirming that they regulate the num-
ber of islet-1+ cells in the rodent brain through LXRs. 
Moreover, the effects of these acids were blocked 
by GGPP (Figure 4D), further suggesting that the 
observed effects were mediated by LXR receptors.
Interestingly, 26-HC, a precursor of cholestenoic 
acids in the acidic pathway of bile acid biosynthesis 
(18) that had no LXR activational effect in luciferase 
assays in neural cells (Figure 2 and ref. 6), also exhib-
ited no effect on the number of islet-1+ cells (data not 
shown). Furthermore, the effects of 3β,7α-diHCA, 3β,7β-diHCA, 
and 3β-HCA on islet-1+ cells were not altered by the known LXR 
ligand 22R-HC (Supplemental Figure 3C), which does not show 
an effect toward islet-1+ cells (6). These findings are very exciting, 
as none of the previously known endogenous brain LXR ligands 
regulates the function of motor neurons. We recently reported that 
brain endogenous LXR ligands selectively regulate neurogenesis 
and/or survival of other cell populations in the developing mid-
brain (6). We thus sought to examine the mechanism by which 
3β,7α-diHCA and 3βH,7O-CA increase the number of islet-1+ cells 
and studied their role in neurogenesis, proliferation, and motor 
neuron survival in the developing brain.
3β,7α-diHCA promotes rodent oculomotor neuron survival in 
vitro, whereas 3β,7β-diHCA and 3β-HCA are toxic. Neurogenesis 
was examined in BrdU pulse-chase experiments, in which neuro-
nal progenitors in primary cultures are labeled with a pulse of BrdU 
at the beginning of the experiment and then are examined for their 
differentiation into motor neurons, as assessed by the acquisition 
Figure 3. Effects of cholestenoic acids on zebrafish motor 
neurons. Tg[isl1:GFP] embryos were incubated with 10 μM test 
compound or vehicle added to medium, and the medium was 
replaced every 12 hours with fresh solution (containing test 
compound or vehicle). Immunocytochemistry was performed 
using an anti-GFP antibody at 48 hpf. (A) Dorsal (top) and 
dorsolateral (bottom) views of the head/upper back region 
of embryos treated with vehicle, 3β,7α-diHCA, or 3βH,7O-
CA. Arrows indicate loci III, IV, V, VII, and X (37), which are 
evolutionarily homologous to the cranial nerves in humans 
(40). Locus III contains the oculomotor neurons, locus IV the 
trochlear neurons, locus V the trigeminal motor neurons, locus 
VII the facial motor neurons, and locus X the cell bodies of the 
vagus nerve. Scale bar: 50 μm. (B) Quantification of islet-1–
GFP signal intensity in the different loci (n = 4). 24,25-EC was 
used as a positive control. (C and D) mRNA levels of (C) isl1 and 
(D) abca1 after treatment with the indicated compounds. Data 
are mean ± SEM (n = 3). *P < 0.05, **P < 0.01 vs. respective 
vehicle, Mann-Whitney test. 
The Journal of Clinical Investigation   R e s e a R c h  a R t i c l e
4 8 3 5jci.org   Volume 124   Number 11   November 2014
Figure 4. Specific cholestenoic acids increase the number of islet-1+ oculomotor neurons, promote neuronal survival, or are toxic in mouse E11.5 brain 
primary cultures. (A) Dose-response curves for quantification of islet-1+ cells in mouse E11.5 brain primary cultures from WT embryos treated with the 
indicated compounds. *P < 0.05 vs. vehicle for ≥5 μM 3β,7α-diHCA, ≥10 μM 3βH,7O-CA, ≥2 μM 3β,7β-diHCA, and ≥2 μM 3β-HCA, Mann-Whitney test.  
(B) Representative islet-1– and NKX6.1-stained cell nuclei treated with 3β,7α-diHCA (10 μM), 3βH,7O-CA (10 μM), 3β,7β-diHCA (2 μM), or 3β-HCA (2 μM).  
(C) Quantification of islet-1+ cells in primary cultures from WT or Lxra–/–Lxrb–/– embryos treated with 3β,7α-diHCA or 3βH,7O-CA (10 μM). *P < 0.05 vs. 
vehicle, Mann-Whitney test. (D) Effect of 10 μM GGPP on treatment in the WT group. *P < 0.05, Mann-Whitney test. (E) Dose-response curves for quanti-
fication of active caspase-3+ cells in mouse E11.5 brain primary cultures. Very high cell death in the cultures is denoted by ¶. *P < 0.05 vs. vehicle for ≥10 μM 
3β,7α-diHCA, ≥2 μM 3β,7β-diHCA, and ≥2 μM 3β-HCA, Mann-Whitney test. (F) Representative active caspase-3– and islet-1–stained cell nuclei treated as 
in B. (G) Quantification of active caspase-3+ cells in primary cultures (WT group) treated as indicated, with or without 10 μM GGPP. *P < 0.05 vs. vehicle or 
as indicated by brackets, Mann-Whitney test. All data are mean ± SEM (n = 3). Scale bars: 20 μm. 
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ber of BrdU+ cells in the cultures (Supplemental Figure 6B), which 
suggests that they do not modulate proliferation. Finally, we tested 
whether cholestenoic acids regulate neuronal survival, as assessed 
by active caspase-3 staining to detect the number of cells undergo-
ing apoptosis in the cultures. Interestingly, treatment with 3β,7α-
of islet-1 expression, a marker for motor neuron fate (41). Surpris-
ingly, none of the cholestenoic acids studied affected the number 
of double-positive BrdU+islet-1+ cells (Supplemental Figure 6A), 
which indicates that they do not promote motor neuron neurogene-
sis. Similarly, none of the cholestenoic acids affected the total num-
Figure 5. Competition between cholestenoic acid effects, and 3β,7α-diHCA promotes motor neuron survival in vivo. (A–C) TR-FRET LXRβ coactivator 
assays. (A) The effect of 10 μM 3β,7α-diHCA was dose-dependently competed by increasing concentrations (incr.) of 3β,7β-diHCA and 3β-HCA (both  
*P < 0.05 for ≥2 μM). Similarly, (B) the effect of 10 μM 24,25-EC was dose-dependently competed by 3β,7α-diHCA (*P < 0.05 for ≥10 μM), 3β,7β-diHCA 
(*P < 0.05 for ≥10 μM), and 3β-HCA (*P < 0.05 for ≥5 μM), and (C) the effects of 3β,7α-diHCA, 3β-HCA, 3β,7β-diHCA, and 24,25-EC (all 10 μM) were dose-
dependently competed by GGPP (all *P < 0.05 vs. respective no-GGPP group). Data were analyzed by Mann-Whitney test. (D and E) 10 μM 3β,7α-diHCA res-
cued the toxic effect of 2 μM 3β,7β-diHCA or 3β-HCA on islet-1+ cells and reduced neuronal cell death induced by these acids, as indicated by the number of 
active caspase-3+ cells, in mouse E11.5 brain primary cultures. *P < 0.05, **P < 0.01, Mann-Whitney test. (F) Mouse embryos were injected with vehicle or 
cholestenoic acid into the mesencephalic ventricle in utero at E11.5 and collected at E13.5. (G–N) Midbrain coronal sections showing islet-1+ motor neurons 
(green) and neighboring TH+ neurons (red) (G–J), and higher magnification of islet-1+ cells (K–N), for embryos injected with vehicle (G and K), 5 μM 3β,7α-
diHCA (H and L), 1 μM 3β-HCA (I and M), and 1 μM 3β-HCA plus 5 μM 3β,7α-diHCA (J and N). (O) Quantification of islet-1+ cell number in each group.  
*P < 0.05, **P < 0.01, 1-way ANOVA with LSD post-hoc test. Scale bars: 100 μm (G–J); 20 μm (K–N). All data are mean ± SEM (n = 3).
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3β,7α-diHCA promotes survival of rodent motor neurons in vivo 
and prevents toxicity by 3β-HCA. In order to examine whether the 
observed effects of cholestenoic acids on motor neuron survival 
could also be detected in the mammalian brain in vivo, we per-
formed cholestenoic acid injections into the cerebral aqueduct of 
E11.5 mice in utero and analyzed brain sections at the midbrain 
level at E13.5 (Figure 5F). While only occasional double-positive 
islet-1+activate caspase-3+ cells remained at the end of the experi-
ment (Supplemental Figure 7), reliable cell counts could be per-
formed for islet-1 and TH (Figure 5, G–O). 3β,7α-diHCA did not 
affect the number of TH+ neurons, but increased the number of 
islet-1+ oculomotor neurons, indicative of a selective survival effect 
of 3β,7α-diHCA on oculomotor neurons in vivo. Upon injection of 
3β-HCA, the number of islet-1+ oculomotor neurons was reduced, 
showing the toxic effect of this metabolite on motor neurons in 
vivo. Finally, coinjection of 3β-HCA and 3β,7α-diHCA reversed 
the loss of oculomotor neurons induced by 3β-HCA, indicating 
that 3β,7α-diHCA protects oculomotor neurons against choleste-
noic acids such as 3β-HCA in vivo. These data further confirm the 
specificity of the neuronal survival and toxic effects of these cho-
lestenoic acids on islet-1+ neurons, but not TH+ neurons, as well as 
the competitive interaction between prosurvival and toxic chole-
stenoic acids on motor neurons in vivo.
In summary, our results indicate that cholestenoic acids reg-
ulate the number of islet-1+ motor neurons by controlling islet-1 
expression (3βH,7O-CA) and competitively regulating neuronal 
survival in a positive (3β,7α-diHCA) or negative (3β,7β-diHCA 
and 3β-HCA) manner.
Discussion
The results presented herein show that cholestenoic acids are 
not mere intermediate metabolites of bile acid biosynthesis, but 
rather represent a diverse family of bioactive compounds capable 
of regulating nuclear receptor function. Cholestenoic acids were 
found to specifically activate LXR and elicit an exquisite array of 
functions, ranging from the regulation of islet-1 expression to the 
positive and negative regulation of motor neuron survival both in 
vitro and in vivo. Moreover, our findings identified cholestenoic 
acids in human CSF to be deregulated in plasma of CTX and SPG5 
patients. Importantly, an absence of neuroprotective cholestenoic 
acids was found in CTX patient plasma, while a combination of 
decreased neuroprotective and increased toxic cholestenoic acids 
was detected in SPG5 plasma. These results are consistent with 
cholestenoic acids being key regulators of motor neuron function 
in development and disease.
Cholesterol is present at high levels in the CNS of vertebrates 
and is metabolized in brain predominantly to 24S-HC (42), which 
accounts for about two-thirds of brain cholesterol metabolism (43). 
Low levels of 26-HC have been found in human and mouse brain 
(Supplemental Results and Supplemental Table 4) and in human 
CSF, where it may be imported from the blood (25, 44–46). Con-
versely, 7αH,3O-CA, a metabolic product of 26-HC, is exported 
from brain to blood in humans (26). In the current study, we found 
4 intermediates in the biosynthesis of 7αH,3O-CA from 26-HC 
via CYP27A1 and CYP7B1 to be present in normal CSF: 3β-HCA, 
3β,7α-diHCA, 7α,26-diHC, and 7α,26-diHCO (Figure 1A). While 
3β-HCA and 7α,26-diHC were previously found in human neu-
diHCA over a wide range of concentrations decreased the number 
of active caspase-3+ cells, whereas 3βH,7O-CA had no effect (Figure 
4, E and F). Since proliferation, neurogenesis, and cell death were 
not affected by 3βH,7O-CA, we attribute the increase in islet-1+ 
cells to an increase in differentiation, given the known role of islet-1 
in this process (20). Cholestenoic acids that reduced the number 
of islet-1+ cells were also examined for their capacity to induce cell 
death in oculomotor neuron cultures. Interestingly, low concentra-
tions of either 3β,7β-diHCA or 3β-HCA increased the number of 
active caspase-3+ cells (Figure 4, E and F), with toxicity starting at 
1 μM. No surviving cells were detected when cultures were treated 
with concentrations of 3β,7β-diHCA or 3β-HCA higher than 5 μM. 
Time-course experiments showed that toxicity was evident after 
2 days of incubation (Supplemental Figure 5B).
The survival-promoting effect of 3β,7α-diHCA was completely 
blocked by coincubation with GGPP (Figure 4G), which indicated 
that this effect was mediated by LXR. Conversely, the cell death 
effects of 3β,7β-diHCA or 3β-HCA (at 2 μM) were not blocked by 
GGPP (Figure 4G), which suggested that the survival-promoting 
effects of 3β,7α-diHCA, but not the toxic effects of 3β,7β-diHCA or 
3β-HCA, were mediated by LXR.
We next examined whether the toxic effects of 3β,7β-diHCA 
or 3β-HCA could be mediated by receptor blockade or competi-
tion. We first performed a binding and activation FRET assay 
using 3β,7α-diHCA at its most effective concentration and increas-
ing concentrations of 3β,7β-diHCA or 3β-HCA. We found that 
3β,7β-diHCA and 3β-HCA reduced the binding of 3β,7α-diHCA in 
a dose-dependent manner (Figure 5A), which indicates that these 
toxic cholestenoic acids compete with the neuroprotective 3β,7α-
diHCA for binding to the LXRβ-LBD. Ki values were 0.91 μM for 
3β-HCA and 1.22 μM for 3β,7β-diHCA.
Furthermore, we performed competition experiments using 
the known LXR ligand 24,25-EC (at its most effective concen-
tration) and increasing concentrations of each of the choleste-
noic acids studied. 3β,7α-diHCA, 3β-HCA, and 3β,7β-diHCA each 
reduced the binding of 24,25-EC to the LXRβ-LBD in a dose-depen-
dent manner (Figure 5B), which suggests that each of these cho-
lestenoic acids competes with 24,25-EC for binding to the LXRβ-
LBD. 3β-HCA had the lowest Ki value (3β,7α-diHCA, 3.56 μM; 
3β,7β-diHCA, 3.45 μM; 3β-HCA, 2.43 μM).
In order to further prove that 3β,7α-diHCA, 3β-HCA, and 3β,7β-
diHCA are specific LXR ligands in neural cells, we incubated the 
acids with GGPP (6). This antagonized and inhibited the ligand-
dependent induction of FRET by 3β,7α-diHCA, 3β-HCA, and 
3β,7β-diHCA as well as by the known LXR ligand 24,25-EC (Figure 
5C), which indicates that 3β,7α-diHCA, 3β-HCA, and 3β,7β-diHCA 
bind to LXRs. The Ki values for the compounds of interest when 
incubated with GGPP were 3.96 μM for 24,25-EC, 1.95 μM for 
3β,7α-diHCA, 2.51 μM for 3β,7β-diHCA, and 2.02 μM for 3β-HCA.
We next tested whether 3β,7α-diHCA could also compete and 
reduce the toxic effect of 3β,7β-diHCA or 3β-HCA. Treatment 
with 10 μM 3β,7α-diHCA reversed the loss of islet-1+ cells and the 
increased number of activated caspase-3+ cells induced by 2 μM of 
3β,7β-diHCA or 3β-HCA (Figure 5, D and E). These observations 
reinforce the notion of balance between the survival- and death-
inducing effects of cholestenoic acids and suggest a new avenue 
for therapeutic intervention.
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motor neuron cultures, which showed that only 3β,7α-diHCA and 
3βH,7O-CA increased the number of islet-1+ neurons (Figure 4, 
A–D). Importantly, their activity was specific to and mediated by 
LXR, as their biological activities were eliminated in cultures from 
Lxra–/–Lxrb–/– mice or by the LXR inhibitor GGPP. The effect of 
3β,7α-diHCA on WT cultures was accompanied by a decrease in 
the number of active caspase-3+ cells (Figure 4E), but no change 
in neurogenesis or proliferation was detected (Supplemental Fig-
ure 6), which indicates that the mechanism by which it increased 
the number of motor neurons was by promoting neuronal survival. 
In vivo experiments performed on embryonic brain in utero con-
firmed this neuroprotective effect of 3β,7α-diHCA on oculomotor 
neurons (Figure 5, G–O). In contrast, 3βH,7O-CA had no effect on 
cell death, neurogenesis, or survival in WT cultures, but increased 
the expression of islet-1, which suggested that it promoted the 
maturation of precursor cells into islet-1+ neurons. Analysis of 
the function of 3β,7β-diHCA and 3β-HCA revealed a toxic effect, 
manifested by an increase in the number of active caspase-3+ cells 
at low concentrations (Figure 4E). Thus, our results indicated that 
only some of the cholestenoic acids capable of activating LXR pro-
mote motor neuron development. Intriguingly, our findings also 
suggested that cholestenoic acids regulate motor neuron number 
by distinct mechanisms regulating differentiation and survival. 
Moreover, we found that the regulation of motor neuron survival 
could be either positive, as shown by the neuroprotective effect of 
3β,7α-diHCA, or negative, as shown by the toxic effect of 3β,7β-
diHCA and 3β-HCA (Figures 4 and 5). These results were quite 
unexpected, but correlated very well with the cholestenoic acid 
profiles in patients with the human diseases CTX and SPG5 (char-
acterized by mutations in CYP27A1 and CYP7B1, respectively) that 
may present with signs of motor neuron loss. Indeed, we found 
that 3β-HCA, one of the LXR ligands identified to have a toxic 
effect, was present at higher levels in SPG5 patients in both plasma 
and CSF (Figure 1, C and G, and Supplemental Tables 1 and 2). At 
the same time, the LXR ligand found to be neuroprotective, 3β,7α-
diHCA, was present at lower levels in SPG5 patients and absent 
in CTX patients (Figure 1, D and H). These observations suggest 
a double-hit model for SPG5, in which loss of motor neurons is 
effected by both mechanisms, whereas for CTX we propose that 
the predominant mechanism would be loss of neuroprotection. 
Moreover, our finding that the neuroprotective cholestenoic acid 
3β,7α-diHCA prevented the loss of oculomotor neurons induced 
by 3β-HCA, both in vitro and in vivo, suggests a possible applica-
tion of 3β,7α-diHCA in the treatment of both SPG5 and CTX. The 
fact that deletion of LXRs results in early developmental motor 
neuron loss (1), while the onset of disease in SPG5 or CTX is usu-
ally in adolescent or adults, indicates that additional endogenous 
LXR ligands may partially compensate for the loss of 3β,7α-diHCA 
in SPG5 and CTX patients. Future studies should examine wheth-
er 3β,7α-diHCA and other yet-unidentified LXR ligands represent 
useful therapeutic tools to treat these and perhaps other devastat-
ing diseases affecting motor neurons.
In summary, we identified 3β,7α-diHCA and 3β,7β-diHCA as 
LXR ligands present in human CSF. Of these, 3β,7β-diHCA and 
the previously identified LXR ligand 3β-HCA were found to cause 
cell death, and the latter was present at high levels in patients with 
SPG5. Instead, 3β,7α-diHCA, which was found at low levels in 
ral tissue (46, 47), 3β,7α-diHCA and 7α,26-diHCO have not been 
previously found in neural tissue or CSF. Importantly, the identi-
fication of these intermediates in the biosynthesis of 7αH,3O-CA 
lends further support to the hypothesis that 7αH,3O-CA is biosyn-
thesized in the human brain (26). This pathway is also conserved 
in rodents, in which 26-HC is the precursor for the synthesis of 
3β-HCA in fetal neurons and of 3β,7α-diHCA and 7αH,3O-CA 
in fetal astrocytes (Figure 1A and ref. 48). There have been few 
studies of specific brain regions for cholestenoic acids; however, 
human retina has been found to contain 3β-HCA at a level of up to 
130 pmol/mg protein, about 10% of the level of 24S-HC in brain 
gray matter (47), whereas in chronic subdural hematoma, 7αH,3O-
CA has been found at a level of 1.5 μM (49). Future studies will be 
directed at profiling cholestenoic acids in distinct brain regions. 
Surprisingly, Cyp7b1–/– and Cyp27a1–/– mice, unlike human SPG5 
patients and some CTX patients, do not suffer from motor neuron 
disease, despite an absence of 3β,7α-diHCA in brain and plasma 
(Supplemental Table 4). These findings suggest that other LXR 
ligands may compensate for the accumulative effect of altered lev-
els of cholestenoic acids in Cyp7b1–/– and Cyp27a1–/– mice.
Classic studies by Lehmann et al. (4) and Janowski et al. (3) 
defined the general structural requirements of steroidal LXR 
ligands to be a 3β-hydroxy-5-ene function in the ring system and 
a hydroxy, oxo, or epoxide function on the C-17 side-chain (3, 4). 
The side-chain functions have more recently been extended to 
include a carboxylic acid group (7, 50), a functional group that is 
also present in the synthetic nonsteroidal LXR ligand GW3965. 
In the current study, we confirmed the LXR-activational capacity 
of cholestenoic acids with a 3β-hydroxy-5-ene structure in neural 
cells and showed that despite the introduction of a 7α-hydroxy, 
7β-hydroxy, or 7-oxo group, LXR activity was maintained. On 
the contrary, the 3-oxo-4-ene equivalents of these acids were not 
LXR ligands. Thus, 3β-HCA, 3β,7α-diHCA, its 7β-isomer (3β,7β-
diHCA), and the necessary 7-oxo intermediate in the epimeriza-
tion reaction (3βH,7O-CA) are all LXR ligands effective at micro-
molar concentrations. Moreover, none of these acids were found 
to activate FXR, VDR, or NURR1 in neural cells, thereby confirm-
ing the specificity of their effect on LXR.
Numerous studies in recent years have linked LXR to neuronal 
degeneration (2, 5, 51–53). These studies have used Lxrb–/– and Lxra–/– 
Lxrb–/– mice. Indeed, both LXR isoforms are expressed in brain (1, 
54), and the knockout mice show progressive lipid accumulation 
in brain, abnormal BBB, increased reactive microglia, astrogliosis, 
and degeneration of adult spinal cord motor neurons (2, 5). Inter-
estingly, a decrease in the number of oculomotor neurons was also 
detected during development in Lxra–/–Lxrb–/– mice at E11.5 (1). 
However, the identity of endogenous brain LXR ligands that regu-
late motor neuron function was unknown. Here we used zebrafish 
to study the in vivo function of acidic LXR ligands newly identified 
in human CSF (i.e., 3β,7α-diHCA and 3β,7β-diHCA), and the 7-oxo 
intermediate in their epimerization, to study the effect of these 
molecules on islet-1+ cranial motor neurons. While metabolites 
that did not activate LXR, such as 7αH,3O-CA, did not regulate 
islet-1 expression, the LXR ligands 3β,7α-diHCA and 3βH,7O-CA 
enhanced isl1 transcript expression in zebrafish embryos (Figure 3), 
effects that were abolished by injection of lxr MO (Supplemental 
Figure 4). These effects were confirmed in rodent primary oculo-
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antibody, a fluorescein-labeled coactivator peptide, and the LXRβ-
LBD tagged with glutathione-S-transferase (GST). Binding of the 
agonist/ligand to the LXRβ-LBD causes a conformational change 
that increases the affinity of LXRβ for the coactivator peptide. Close 
proximity of the fluorescently labeled coactivator peptide to the 
terbium-labeled antibody increases the TR-FRET signal intensity. 
The 520:495 TR-FRET ratio was calculated using a Victor multila-
bel reader with an excitation wavelength of 340 nm and emission 
wavelengths of 520 nm and 495 nm. The activational capacity of 
potential ligands was tested in a 382-well polypropylene plate fol-
lowing the manufacturer’s protocol.
Zebrafish experiments. Zebrafish were raised on a 14-hour day/ 
10-hour night cycle and kept at 28.5°C. Tg[isl1:GFP] embryos were 
obtained via natural spawning and staged in hours postfertiliza-
tion (hpf) or days post fertilization, according to Kimmel et al. (57). 
Embryos older than 24 hpf were treated with 0.03% phenylthiourea 
(PTU) to inhibit pigmentation. MO injections were performed using 
splice site–specific zebrafish lxr MO, as previously reported (58). MO-
injected embryos were immediately dechorionated, transferred to 
a 96-well plate, and exposed to DMSO- or ligand-treated medium. 
Tg[isl1:GFP] embryos were collected by natural mating, immediately 
dechorionated (at the 1-cell stage), and transferred to a 96-well plate. 
Each compound tested was obtained as 10 mM stock and diluted in 
embryo medium to a final concentration of 10 μM, and 200 μl was 
added to each well. DMSO- or propan-2-ol–treated embryo medium 
was used as control. Ligand solutions were replaced every 12 hours 
with fresh ligand solution prepared in PTU-treated embryo medium. 
Embryos were collected at 48 hpf, fixed for 4 hours at room tempera-
ture with 4% paraformaldehyde (PFA), and then washed and kept in 
PBST. Immunocytochemistry was performed using an anti-GFP anti-
body, and fluorescence was viewed and photographed using a Zeiss 
Axioplan compound microscope and a Zeiss Axiocam digital camera.
Quantitative PCR. Total RNA was extracted from SN4741 cells 
and from zebrafish treated with the compounds of interest using 
the RNeasy Mini Kit (Qiagen); 1 μg was treated with RQ1 RNase-
free DNase (Promega) and reverse transcribed using SuperScript II 
Reverse Transcriptase (Invitrogen) and random primers (Invitro-
gen) (RT+ reaction). Parallel reactions without reverse transcriptase 
enzyme were performed as a control (RT– reaction), and Sybergreen 
real-time quantitative PCR assays were carried out. Expression levels 
were obtained by normalization to the value of the housekeeping gene 
encoding actin or 18S, obtained for every sample in parallel assays.
Mice. Mice were housed, bred, and treated according to the guide-
lines of the European Communities Council (directive 86/609/EEC) 
and the Society for Neuroscience. Lxra–/–Lxrb–/– mouse cell cultures 
were from the colony at the Department of Biosciences and Nutri-
tion at Novum, Karolinska Institutet. Male and female WT and Lxra–/– 
Lxrb–/– mice were generated as previously described (59, 60). Mice 
were backcrossed onto a C57BL/6 background for 10 generations. 
Male Cyp7b1–/– mouse brain and plasma were from animals gener-
ated at the University of Edinburgh. Male mice homozygous for tar-
geted disruption of the Cyp7b1 gene (61) congenic on the C57BL/6 
genetic background (>15 generations backcrossed to C57BL/6) and 
WT littermate controls were generated from Cyp7b1–/+ crosses. Male 
Cyp27a1–/– mouse tissue and plasma was purchased from The Jackson 
Laboratory (strain B6.129-Cyp27a1tm1Elt/J; ref. 62). The Cyp27a1–/– 
colony was backcrossed to C57BL/6J inbred mice for approximately 
SPG5 and absent in CTX patients, promoted motor neuron surviv-
al, while 3βH,7O-CA regulated islet-1 expression levels. Thus, our 
results uncovered several novel functions of cholestenoic acids 
and identified them as LXR ligands and key regulators of motor 
neuron function in development and disease. We suggest that 
factors with neuroprotective function, such as 3β,7α-diHCA, may 
thus find a therapeutic application to prevent motor neuron loss. 
This suggestion is supported by our finding that 3β,7α-diHCA, a 
cholestenoic acid that decreased in SPG5, prevented cell loss by 
3β-HCA, a cholestenoic acid that accumulates in SPG5.
Methods
Extraction of sterols. Sterols were extracted from CSF, plasma, or 
mouse brain into ethanol and fractionated by reversed phase solid 
phase extraction (SPE) to give a cholestenoic acid– and oxysterol-rich 
fraction devoid of cholesterol (7, 55, 56).
Charge-tagging of sterols. The sterols were charge-tagged with 
the GP-hydrazine as described previously (7, 55, 56). This greatly 
enhances their response when analyzed by LC-ESI-MS and tandem 
mass spectrometry (MSn).
Reagents. HPLC-grade water and solvents were from Fisher Sci-
entific or Sigma-Aldrich. Authentic sterols, steroids, cholestenoic 
acids, bile acids, and their precursors were from Avanti Polar Lipids, 
Steraloids, Sigma-Aldrich, or from previous studies in our laboratories. 
Girard P (GP) reagent [1-(carboxymethyl)pyridinium chloride hydra-
zide] was from TCI Europe or synthesized in earlier studies, and cho-
lesterol oxidase from Streptomyces sp. was from Sigma-Aldrich. Certi-
fied Sep-Pak C18 200 mg SPE cartridges were from Waters. Luer-lock 
syringes were from BD Biosciences.
LC-ESI-MSn on the LTQ-Orbitrap. LC-ESI-MS and LC-ESI-MSn 
were performed using an Ultimate 3000 HPLC system (Dionex) 
linked to the ESI source of a LTQ-Orbitrap XL or LTQ-Orbitrap Velos 
(Thermo Fisher) mass spectrometer as described previously (7, 55, 56).
Luciferase reporter assay. The ability of oxysterols and their acidic 
metabolites to activate several nuclear receptors (i.e., LXRα, LXRβ, 
FXR, VDR, and NURR1) was tested in luciferase assays. Transient 
transfection studies were performed in the mouse neuronal cell 
line SN4741. This cell line was selected because the oxysterols and 
acidic metabolites tested were initially identified in CSF. Cells were 
plated in 24-well plates (5 × 105 cells/well) 24 hours before transfec-
tion and transfected with 1 μg plasmid DNA/well complexed with 
2 μl Lipofectamine 2000 (Invitrogen). Cells were transfected with 
400 ng of a LXR-, FXR-, VDR-, or NURR1-responsive luciferase 
reporter construct and 200 ng LXRα, LXRβ, FXR, VDR, or NURR1. 
A reporter gene expressing the Renilla luciferase (pRL-TK; Promega) 
was cotransfected in all experiments as an internal control for nor-
malization of transfection efficiency. After a 12-hour incubation, the 
lipid/DNA mix was replaced with fresh 2.5% serum medium contain-
ing vehicle or appropriate ligand (10 μM), as specified in each experi-
ment. The ability of cholestenoic acids to activate LXR was confirmed 
in experiments with or without the LXR inhibitor GGPP (10 μM) also 
added to the medium. Luciferase activities were assayed 24 hours 
later using the Dual-Luciferase Reporter Assay System (Promega), 
following the manufacturer’s protocol.
LXRβ ligand binding assay. For LXRβ ligand binding activity 
measurement, we used the Lanthascreen TR-FRET LXRβ Coactiva-
tor Assay (Invitrogen). The assay uses a terbium-labeled anti-GST 
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were obtained on a cryostat. 14-μm serial coronal sections through 
the midbrain region were cut on a cryostat and placed serially on 10 
slides. Slides 1 and 6 were subjected to immunohistochemistry. Sec-
tions were preincubated for 1 hour in blocking solution followed by 
incubation at 4°C overnight with the following primary antibodies: 
anti-TH (1:750, Pel-Freeze), anti–islet-1 (1:100; Developmental Stud-
ies Hybridoma Bank), and anti–cleaved caspase-3 (Asp175) (1:100; 
Cell Signaling Technology). After washing, slides were incubated 
for 1–2 hours at room temperature with the appropriate fluorophore-
conjugated (Cy2, Cy3, and Cy5, 1:300, Jackson Laboratories; Alexa 
Fluor 488, Alexa Fluor 555, and Alexa Fluor 647, 1:1,000, Invitrogen) 
secondary antibodies. Confocal images were taken with a Zeiss LSM5 
Exciter or LSM700 microscope.
Statistics. Statistical analyses (Mann-Whitney test, Dunnett T3 
test, and 1-way ANOVA with LSD post-hoc test) were performed 
using Prism 4 (GraphPad Software). All data represent mean ± SEM. A 
P value less than 0.05 was considered significant.
Study approval. Human samples, collected according to the 
principles of the Declaration of Helsinki, were provided to Univer-
sity Hospital Basel, Barts Health NHS Trust, St. Mary’s Hospital, 
Institute of Child Health, Conegliano Research Centre, Federico II 
University, University of Tubingen, Kurume University School of 
Medicine, and University Hospital “Attikon” with written informed 
consent and IRB and ethical approval. Ethical approval was granted 
by Stockholm Norra Djurförsöksetisks Nämnd for zebrafish experi-
mentation (nos. N293/09 and N338/10), mouse experimentation 
(nos. N154/06, N145/09, N370/09, and N273/11), and in utero 
experimentation (no. N486/12).
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12 generations by the donating investigator (62) prior to sending to 
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C57BL/6J inbred mice for at least 1 generation to establish the colony. 
WT animals from the colony were used as controls. Tissue and blood 
sampling from these mice was performed under the aegis of the UK 
Scientific Procedures (Animals) Act, 1986.
Primary midbrain cultures. Brains from E11.5 mice were obtained, 
and the midbrain region was dissected, mechanically dissociated, 
plated on poly-d-lysine (150,000 cells/cm2), and grown in serum-free 
N2 media consisting of F12/DMEM (1:1 mixture) with 10 ng/ml insu-
lin, 100 μg/ml apo-transferrin, 100 μM putrescine, 20 nM progester-
one, 30 nM selenium, 6 mg/ml glucose, and 1 mg/ml BSA. Cells were 
treated for 3 days in vitro with the compounds of interest, fixed with 
4% PFA, and processed for staining using appropriate antibodies.
For BrdU analysis, cells were treated with BrdU 1 hour after plat-
ing, and media was replaced with fresh medium after 16 hours. After 
a further 2 days in culture, cells were treated for 30 minutes with 2N 
HCl, and immunocytochemistry was performed to evaluate the num-
ber of double-positive BrdU+islet-1+ cells (a measure of motor neuron 
neurogenesis). Hoechst staining was performed by permeabilizing 
cells with a 0.3% Triton-X 100/PBS solution for 5 minutes followed by 
incubation with Hoechst 33258 (Sigma-Aldrich) for 10 minutes.
Immunocytochemistry. Cells were fixed in 4% PFA, washed in PBS, 
and blocked in 5% normal goat serum/PBS for 1 hour at room tem-
perature. Primary antibodies were diluted in PBS (pH 7.4), 0.3% Tri-
ton X-100, and 1% BSA, and incubations were carried out overnight 
at 4°C or at room temperature for 2 hours. The antibodies used were 
anti-BrdU (diluted 1:400; Abcam), anti–islet-1 (1:100; Developmental 
Studies Hybridoma Bank), anti–cleaved caspase-3 (Asp175) (1:100; 
Cell Signaling Technology), anti-TH (1:1,000; Pel-Freeze), anti-GABA 
(1:1,000; Sigma-Aldrich), anti-BRN3A (1:250; Millipore), anti-NKX6.1 
(1:200; Novus Biologicals), anti-ChAT (1:500; Millipore), and appro-
priate secondary antibodies (Jackson ImmunoResearch or Alexa). 
Cells positive for the corresponding marker were counted directly at 
the microscope at ×20 magnification. Cells were counted in every well 
— in 8 consecutive fields (from one side of the well to the other, passing 
through the center) — in 3 different wells per experiment and 3 dif-
ferent experiments per condition. Random images of the wells were 
taken for every condition to document the result, and representative 
images were subsequently selected to represent the quantitative data. 
Photos were acquired with a Zeiss Axioplan microscope and a Hama-
matsu camera C4742-95 using Openlab software.
Intraventricular injections in utero. Female WT CD-1 mice (25–35 g; 
Charles River Breeding Laboratories) were used for these experi-
ments. For embryo analyses, WT CD-1 mice were mated overnight, 
and noon of the day the plug was considered E0.5. E11.5 pregnant 
females were deeply anesthetized using isofluorane (IsoFlo; Abbott 
Labs), and the uterine horns were accessed through an abdominal 
incision. 1 μl 3β,7α-diHCA (5 μM) or 3β-HCA (1 μM) or vehicle solution 
(isopropanol; 50% v/v) was injected into the cerebral aqueduct. The 
uterine horns were replaced into the abdominal cavity, which was then 
closed with sutures. Embryos were analyzed 48 hours later.
Immunohistochemical analysis of rodent embryos. Embryos were 
dissected out of the uterine horns in ice-cold PBS, fixed in 4% PFA 
for 4 hours to overnight, cryoprotected in 15%–30% sucrose, fro-
zen in Tissue-Tek OCT compound (Sakura Finetek) on dry ice, and 
stored at –80°C until use. Serial coronal 14-μm sections of the brain 
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